Vitamin D is recognized as a vital nutrient that serves as a precursor to the hormone calcitriol, which is essential for various bodily functions, including bone health, muscle function, and immune response. Recent research published in Frontiers in Endocrinology has identified the SDR42E1 gene as a key player in the absorption and metabolism of vitamin D from the gut. This discovery may have significant implications for precision medicine, particularly in cancer treatment.
Dr. Georges Nemer, a professor at Hamad Bin Khalifa University, noted that inhibiting SDR42E1 could selectively impair the growth of cancer cells. This conclusion stemmed from earlier studies linking mutations in the SDR42E1 gene to vitamin D deficiency. The research team utilized CRISPR/Cas9 gene editing to create a non-functional version of the SDR42E1 gene in colorectal cancer cells (HCT116). The alteration resulted in a 53% decrease in cell viability, indicating that SDR42E1 plays a crucial role in maintaining the health of these cells.
The study revealed that more than 4,600 downstream genes exhibited altered expression levels, highlighting SDR42E1's involvement in numerous cellular processes, particularly those related to cancer signaling and cholesterol metabolism. The findings suggest potential avenues for targeted cancer therapies while sparking interest in the possibility of enhancing SDR42E1 levels to leverage the health benefits associated with calcitriol.
However, researchers caution that while the potential applications are promising, further validation and investigation into the long-term effects of manipulating SDR42E1 on vitamin D metabolism are necessary. Dr. Nagham Nafiz Hendi emphasized the importance of a cautious approach, noting that the gene's role in vitamin D regulation could impact various health conditions, including cancer and autoimmune disorders.